ICU Medical (NASDAQ:ICUI) Reaches New 52-Week High – Here’s What Happened

ICU Medical, Inc. (NASDAQ:ICUI) reached a new 52-week high on Monday . The company traded as high as $174.77 and last traded at $174.8530, with a volume of 20705 shares trading hands. The stock had previously closed at $168.51.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ICUI. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th. Piper Sandler reduced their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Needham & Company LLC raised ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 27th. KeyCorp upped their price objective on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Finally, BTIG Research began coverage on shares of ICU Medical in a research note on Monday, June 15th. They set a “buy” rating and a $170.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $172.00.

ICU Medical Stock Performance

The business’s 50-day simple moving average is $148.01 and its two-hundred day simple moving average is $140.23. The firm has a market cap of $4.30 billion, a price-to-earnings ratio of 93.48, a P/E/G ratio of 2.35 and a beta of 0.74. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.19. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business had revenue of $525.77 million for the quarter, compared to analyst estimates of $520.65 million. During the same period in the prior year, the company posted $1.72 EPS. The company’s revenue for the quarter was down 12.3% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, sell-side analysts expect that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director owned 7,960 shares in the company, valued at approximately $978,363.60. This represents a 23.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On ICU Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Maryland State Retirement & Pension System lifted its holdings in ICU Medical by 2.0% during the fourth quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after purchasing an additional 70 shares in the last quarter. California Public Employees Retirement System increased its stake in shares of ICU Medical by 0.3% during the first quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after purchasing an additional 90 shares in the last quarter. Oregon Public Employees Retirement Fund raised its position in shares of ICU Medical by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after purchasing an additional 100 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the last quarter. Finally, Lido Advisors LLC lifted its stake in ICU Medical by 4.5% in the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock valued at $354,000 after buying an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.